DVA
DaVita Inc.NYSEHealthcare$145.58-3.17%ClosedMarket Cap: $9.73B
As of 2026-04-06
Valuation
P/E (TTM)
13.03
PEG
—
P/B
-19.25
P/S
0.71
EV/EBITDA
9.09
DCF Value
$317.17
FCF Yield
13.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
30.9%
Operating Margin
14.9%
Net Margin
5.5%
ROE
-160.6%
ROA
7.7%
ROIC
10.7%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $3.62B | 28.3% | $551.2M | $234.2M | $2.45 | — |
| FY 2025 | $13.64B | 27.0% | $2.01B | $746.8M | $9.51 | — |
| Q3 2025 | $3.42B | 31.8% | $505.8M | $150.3M | $2.04 | — |
| Q2 2025 | $3.38B | 33.1% | $537.8M | $199.3M | $2.58 | — |
| Q1 2025 | $3.22B | 30.5% | $438.9M | $162.9M | $2.00 | — |
| Q4 2024 | $3.29B | 32.5% | $565.4M | $259.3M | $3.09 | — |
| FY 2024 | $12.82B | 32.9% | $2.09B | $936.3M | $10.73 | — |
| Q3 2024 | $3.26B | 34.1% | $534.9M | $214.7M | $2.50 | — |
| Q2 2024 | $3.19B | 32.8% | $506.4M | $222.7M | $2.50 | — |
| Q1 2024 | $3.07B | 32.3% | $483.8M | $239.6M | $2.65 | — |
| Q4 2023 | $3.15B | 32.0% | $389.9M | $150.7M | $1.62 | — |
| FY 2023 | $12.14B | 31.5% | $1.60B | $691.5M | $7.42 | — |